March 12, 2024 11:25 AM EDT
R&D

Bris­tol My­ers drops an­oth­er Cy­tomX pro­gram

Katherine Lewin

News Reporter

Bris­tol My­ers Squibb dropped an­oth­er CT­LA-4 pro­gram from its decade-long re­search col­lab­o­ra­tion with Cy­tomX af­ter the big phar­ma re­viewed its port­fo­lio.

Cy­tomX an­nounced the change …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times